In addition to conventional peripheral blood biomarkers, such as AFP, the correlation between PD-L1 expression level, tumor mutational burden (TMB), and other factors, and patient responsiveness to immunotherapy has emerged as a significant research focus. This evidence concerns the gene CD274 and neoplasm.